T he precise pathophysiology of inflammatory bowel disease (IBD) remains to be fully revealed. However, the current prevailing theory maintains that environmental triggers and alterations in gut microbiota in genetically predisposed individuals result in an abnormal immune response and chronic inflammation. Therefore, the main treatment modality has been to alter or suppress immune responses by the use of corticosteroids, immunomodulators, and the wide array of anti-tumor necrosis factor (TNF) or anti-integrin biologics. However, the primary or secondary treatment failure of these agents continues to affect a portion of treated patients. [1] [2] [3] For such refractory disease, alternative treatments have been attempted with varying success, including probiotics, granulocyte-macrophage colony-stimulating factor, and even helminthes. [4] [5] [6] The development of secondary humoral immune deficiency has been postulated as one of the mechanisms leading to failure of conventional treatment in patients with severe IBD. In fact, our previous study suggested that at least a particular subset of patients with IBD have a baseline immunoglobulin (Ig) deficiency, with low IgG and IgG1 levels discovered in 22.7% and 23.4% of patients, respectively. 7 Our more recent study demonstrated an association between low IgG/G1 levels and poor outcomes in Crohn's disease (CD), including the requirement of bowel resection surgery. 8 In this context, intravenous immunoglobulin (IVIG) has been examined as a possible treatment option and has demonstrated promise in the treatment of refractory disease. [9] [10] [11] [12] [13] Unfortunately, previous studies regarding IVIG use in IBD have been limited, largely because of the small number of patients receiving the therapy. As a result, to our knowledge, there are no published data in regard to which patients with IBD may benefit most from this therapy in comparison to their peers. Information regarding possible predictors for IVIG failures and successes could provide important guidance to steering future treatment plans for the patient with refractory IBD.
We therefore sought to assess factors associated with failures in the treatment of refractory IBD with IVIG and to evaluate overall efficacy and safety in 3 individually assessed disease processes: CD, ulcerative colitis (UC), and pouchitis.
PATIENTS AND METHODS

Subject Inclusion and Exclusion Criteria
The Cleveland Clinic Institutional Review Board approved this historical cohort study. Included in the study group were all eligible subjects with (1) a diagnosis of CD, UC, or pouchitis using International Classification of Diseases, Ninth Revision coding; (2) documented treatment failure or incomplete response to medical treatment (5-aminosalicylic acids , corticosteroids, 6-mercaptopurine [6-MP]/azathioprine [AZA], or anti-TNF agents); (3) admission to our inpatient service with an acute exacerbation of IBD, and (4) treatment with IVIG (0.4 g/kg) between June 2010 and November 2014. These patients were sought by a chart review of an electronic database of the Cleveland Clinic Health System. The time of IVIG therapy was regarded as the inception point for the study, and patients were then followed clinically for the pertinent clinical outcomes through July 2016.
As standard treatment at our hospital, all patients receiving IVIG treatment are tested for IgA deficiency. Patients with documented IgA deficiency or with a previous history of an otherwise adverse reaction to IVIG were excluded from the study. All patients who received IVIG were admitted for at least 23 hours, so that adverse reactions if present could be adequately monitored and treated. Further exclusion criteria for the study included the following: (1) a known primary immunodeficiency disorder including common variable immune deficiency and (2) immunodeficiency secondary to HIV infection.
Study Variables
Detailed clinical variables were recorded for all eligible subjects at the time of IVIG treatment. This included basic demographics (age, sex, race, and body mass index), disease type, duration of IBD, number of dispensed doses of IVIG, concomitant cytomegalovirus infection or Clostridium difficile infection (CDI), previous IBD-related treatments (5-ASA, corticosteroids, 6-MP or AZA, methotrexate, anti-TNF agents, or anti-integrin biologics), other treatments used in the same hospitalization (including IV corticosteroids), previous bowel resection surgery including previous ileal pouch-anal anastomosis, and basic laboratory tests the day of IVIG administration (including albumin, hemoglobin [hgb] , white blood cell count [WBC] , and platelet levels).
Outcome Measurements
The primary outcome was defined as changes in diseasespecific severity indices after IVIG administration. The severity of disease both before and after treatment (at a subsequent outpatient visit within a month of discharge) was assessed by way of the partial Mayo Score 14, 15 for UC, the Harvey-Bradshaw index (HBI) 16 for CD, and the modified Pouchitis Disease Activity Index 17 for pouchitis. As a secondary outcome, we examined the duration of surgery-free survival after IVIG administration. IBDrelated bowel surgery included small bowel resection, ileocolonic resection, stricturoplasty, partial colectomy, total proctocolectomy, pouch excision or permanent diversion. Other evaluated outcomes after IVIG administration included any subsequent IBD-related emergency department (ED) visits, hospital readmissions, and mortality. Infusion reactions were also noted and recorded. The occurrence of all these outcomes was measured through July 2016, and the last clinical encounter for the patient at our institution was deemed the final sensor point for all outcomes.
Statistical Analysis
Time-to-event analysis was performed to assess factors associated with need for post-IVIG bowel resection surgery. Follow-up time was defined as number of months from IVIG to bowel resection surgery. Univariable and multivariable Cox regression analysis was performed to assess factors associated with surgery. An automated stepwise variable selection method performed on 1000 bootstrap samples was used to choose the final multivariable model. All baseline variables were considered for inclusion in the multivariable model except categorical variables observed in ,5 subjects; the 3 variables with highest inclusion rates were included in the final model. Univariable Cox regression analysis was also performed to assess factors associated with readmissions, ED visits, and mortality. In addition, logistic regression analysis was performed to assess factors associated with the occurrence of adverse reactions. Finally, paired t tests were used to evaluate changes in disease activity scores before and after IVIG, and regression analysis was used to assess factors associated with change in scores while adjusting for baseline score. All analyses were performed using SAS (version 9.4; The SAS Institute, Cary, NC) and a P , 0.05 was considered statistically significant.
RESULTS
Demographic and Clinical Characteristics
Of 167 patients initially screened, 54 met the inclusion criteria and were formally enrolled in this study, including 21 (38.9%) males, 23 (42.6%) patients with CD, 15 (27.8%) with Table 1 summarizes the demographics and clinical characteristics of the cohort.
Outcomes Figure 1 depicts the various disease activity scores before and after IVIG treatment. All disease severity scores were significantly improved after IVIG administration (Harvey-Bradshaw index P ¼ 0.007, partial Mayo score P ¼ 0.002, modified Pouchitis Disease Activity Index P ¼ 0.008). There was no evidence to suggest that any measured baseline factors were associated with significantly different changes in any of the disease activity scores (data not shown). Table 2 summarizes other measured post-IVIG outcomes of the study. A total of 27 (50%) patients required bowel surgery during the follow-up period, with a mean surgery-free survival of 28.7 6 3.7 months. Thirty-seven percent and 67% of subjects endured subsequent IBD-associated ED visits and readmissions, respectively, whereas 4 of the 54 patients were deceased by the end of follow-up. The causes of death included severe sepsis secondary to recurrent severe CDI, severe sepsis in the setting of severe acute pancreatitis, and 2 unknown cases. Average time to death after IVIG administration for these 4 patients was greater than 9 months. Figure 2 depicts the Kaplan-Meier plots for subsequent ED visits, readmissions, bowel surgery, and mortality after IVIG administration. Mean times to subsequent IBD-related ED visits and readmissions were 38.8 6 4.6 and 13.6 6 2.3 months, respectively. Anti-TNF and anti-integrin biologics were used during post-IVIG follow-up in 15 (27.8%) and 6 (11.1%) cases, respectively. Five (9.3%) patients reported possible infusion reactions, including associated nausea, headaches, chills, and tremors.
Risk Factors for Poor Outcomes Post-IVIG Table 3 presents the univariable and multivariable analysis assessing risk factors associated with bowel surgery after IVIG administration. In univariable analysis, subjects with CDI had a nearly 3-fold increased risk of bowel resection surgery after IVIG compared with those without the infection (hazard ratio [HR] ¼ 2.9, 95% confidence interval [CI], 1.2-7.4; P ¼ 0.023), and results remained consistent in multivariable analysis (HR ¼ 3.0, 95% CI, 1.2-7.6; P ¼ 0.024). Table 4 presents the analysis assessing risk factors associated with other secondary outcomes after IVIG administration, including IBD-related ED visits, IBD-related readmissions, and mortality. CDI was associated with increased risk of recurrent admission after therapy (HR ¼ 2.5, 95% CI, 1.05-5.9; P ¼ 0.038). Increased body mass index (1 kg/m 2 increments) was a risk factor for mortality after IVIG administration (HR ¼ 1.08, 95% CI, 1.00-1.2; P ¼ 0.05), as was increased duration of disease (HR ¼ 0.50, 95% CI, 0.29-0.87; P ¼ 0.014) and increased number of IVIG doses (HR ¼ 1.8, 95% CI, 1.1-2.9; P ¼ 0.018).
DISCUSSION
Our study demonstrated an improvement in all documented disease severity scores with IVIG administration. In addition, we illustrated a number of risk factors for poor outcomes after IVIG therapy for medically refractory IBD. CDI seemed to be particularly associated with these poor outcomes, with a 3-fold increased risk for bowel surgery in multivariable analysis along with an increased risk for recurrent IBD-associated hospitalizations.
IVIG is a blood product solution prepared from thousands of human donors consisting of concentrated IgG immunoglobulins. To date, IVIG has been used in a wide range of autoimmune and inflammatory conditions, including idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome and other autoimmune neuropathies, myasthenia gravis, dermatomyositis, and several other rare diseases. 18, 19 Although the precise pathway by which IVIG impacts autoimmune processes is yet to be fully elucidated, it is thought that the primary mechanism of action may be the blockage of Fc receptors on innate immune effector cells, inhibiting their activation by immune complexes of self-antigens and autoantibodies. 10, 20 Other proposed synergistic mechanisms include the neutralization of autoantibodies by anti-idiotypic antibodies, downregulation of B-cell maturation through idotypemediated inhibition of FcgRIIB B-cell receptors, deactivation of various cytokines, and impediment of complement-mediated damage. 10, 21 To date, IVIG has been demonstrated to have an excellent safety profile with mostly mild and reversible reactions, possibly related with the speed of infusion or minor contaminants. Although documented possible postinfusion side effects have included fever, chills, facial flushing, shortness of breath, back pain, arthralgia, myalgias, hypotension, and shock, these side effects are now far less frequent with newer IVIG formulations. 22 In the setting of previous successes in other various autoimmune pathologies, IVIG has been used in IBD refractory to conventional treatment options on an off-label basis with documented efficacy. [9] [10] [11] [12] [13] One study examined 19 patients with corticosteroid-refractory disease, who were administered IVIG in addition to their regular medications (including an immunomodulator and corticosteroids). At 4 weeks of follow-up, 73.7% had reached clinical remission (Crohn's disease Activity Index ,150), with a mean remission duration of 20.6 months. 13 Another study evaluating 24 patients receiving IVIG for IBD found that 79% of the patients achieved a clinical response or remission, with 62.5% demonstrating endoscopic improvement. 9 Although IVIG has previously demonstrated promising results in the treatment of IBD in these smaller studies, to our knowledge, our study is the first of its kind to assess for factors associated with treatment response of this innovative treatment option. Overall, the mean surgery-free survival for our medically refractory hospitalized cohort of 54 patients was 28.7 6 3.7 months. Interestingly, those with CDI had a 3-fold increased risk for bowel surgery after IVIG administration in both univariable and multivariable analyses. CDI was also a risk factor for IBDrelated readmission in this group. To date, IVIG has actually been examined as a possible last-line therapy in the treatment of resistant CDI, as pooled IVIG may contain antibodies that could theoretically neutralize endotoxins released by the bacteria. 23 The literature on the matter is limited to retrospective chart reviews and case reports, with a lack of randomized controlled trials to date. [23] [24] [25] [26] [27] In the context of medically refractory IBD, CDI may cause further exacerbation of mucosal inflammation that is already pronounced, leading to fecal loss of Ig and thereby limiting the effectiveness of IVIG in these patients.
Other risk factors detected on our analysis included a possible association between higher body mass index, longer duration of disease, and increased number of IVIG doses with mortality. Although the association between increased dosing of IVIG and mortality is admittedly concerning, we strongly suspect that this univariable analysis was hindered by a number of confounding variables, including disease severity. Our cohort group only included 4 mortality outcomes, so we unfortunately did not have the appropriate power to further examine this matter using multivariable analysis.
Overall, our cohort demonstrated significant improvement in clinical disease severity for all patients with IBD and a substantial surgery-free survival time after IVIG therapy, with relatively minimal signs of significant adverse reactions. As such, we believe our study provides additional support for the planning of future prospective trials to further evaluate the efficacy of IVIG therapy in the context of medically refractory IBD. Unfortunately, as of now, IVIG is by no means an inexpensive therapeutic option. 28 With this in mind, and in the context of rare yet plausible adverse reactions, our findings regarding risk factors for IVIG failure may also prove to have profound clinical implications: Our data could lend further important guidance for physicians seeking to identify which patients may obtain particular benefits from IVIG therapy and which patients may not.
The studied cohort group did not receive one standardized regimen of IVIG administration. Recommended dosing for other inflammatory disease states vary depending on the condition, particularly as off-label use becomes increasingly common. 29, 30 Moreover, optimal dosing has not yet been well established in the off-label use of IVIG for refractory IBD, with variable regimens in previous studies demonstrating promising results. [9] [10] [11] [12] [13] Each administration provides immediate immunoglobulin into the blood stream, and response to treatment for FDA-approved indications such as idiopathic thrombocytopenic purpura generally occurs within 1 to 3 days. 30 Most patients in our study group (68.5%) received a single dose of IVIG. It was ultimately left up to the discretion of the treating physician on our inpatient service to determine the individualized therapeutic regimen. It should be acknowledged that this approach likely led to a limitation in the ability to generalize results to the wider patient population.
Although the half-life of IVIG varies among patients, it has been estimated at roughly 31 days. 31 Disease severity scores were therefore reassessed within a month of discharge. We speculate that IVIG therapy played a short-term role in achieving remission in these hospitalized patients with acute IBD exacerbations. Although we hypothesize that IVIG thereby contributed to prolonged time-to-event periods for other disease-related adverse outcomes including surgery, as our study lacks a standard care treatment group for comparison, we were unable to assess these data for statistical disparity.
There were admittedly a few other limitations to our study. For one, as all subjects in our cohort were treated at our tertiary care hospital; there was undoubtedly a component of selection bias with cases more complicated and refractory than those found in the general population. Furthermore, a relatively large percentage of our cohort included patients with ileal pouch-anal anastomosis with courses complicated by pouchitis as a result of the tendencies of clinical practice of one of our coauthors (B.S.). The nature of such a historical cohort study also inevitably lends itself to various unknown confounding factors. Future prospective randomized controlled trials are pivotal to verify our results.
In conclusion, our study demonstrates concomitant CDI as a risk factor for the treatment failure of IVIG in medically refractory IBD. Overall, IVIG also exhibited efficacy in terms of disease severity scores for CD, UC, and pouchitis in this cohort. Future multicenter randomized controlled studies will be critical for further evaluation of IVIG in the treatment of otherwise medically refractory IBD.
